CD34 and central nervous system cancer: Only one of the many studies that have examined CD34 expression in gliomas found tumoral (as opposed to endothelial) immunoreactivity in lesions classified as WHO grade II or III astrocytomas, oligodendrogliomas or oligoastrocytomas [8].